**Specifications Table**TableSubject area*Biology*More specific subject area*Veterinary microbiology, anaerobes, Clostridium perfringens, Clostridium difficile*Type of data*Tables, figures and text*How data was acquired*Analysis of clinical data and characteristics of bacterial isolates*Data format*Filtered and analyzed*Experimental factors*Dogs and cats attended in veterinary clinics, and the Clostridium perfringens and C. difficile isolates obtained from their feces*Experimental features*Analysis of general data about participating clinics, and the demographic and clinical features of recruited animals; genetic and phenotypic profiling of isolates*Data source location*Universidad Complutense de Madrid, Madrid, Spain*Data accessibility*Data is provided with this article*

**Value of the data**•First detailed analysis of the prevalence of *Clostridium perfringens* and *Clostridium difficile* shedding by small animals (dogs and cats) in the Madrid region (Spain).•Detailed phenotypic and genetic data of recovered isolates is provided, which may be useful for comparison in future epidemiological surveys.•Given the recent emergence of antibiotic-resistant strains of *C. difficle*, information on the antimicrobial susceptibility profiles of the isolates obtained in this survey may be particularly valuable.

1. Data {#s0005}
=======

The data shown in [Section 1.1](#s0010){ref-type="sec"} of this article provide detailed information on the veterinary clinics that participated in a recent survey of the prevalence of fecal shedding of *Clostridium perfringens* and *C. difficile* by dogs and cats which was carried out in the Madrid region (Spain) [@bib1]. Furthermore, the demographic and clinical features of recruited animals are detailed in [Section 1.2](#s0015){ref-type="sec"}, and [Section 1.3](#s0020){ref-type="sec"} provides extensive data on the genetic and phenotypic characteristics of recovered bacterial isolates.

1.1. General data about participating clinics {#s0010}
---------------------------------------------

An overview of the 17 veterinary clinics that participated in the study (hereafter referred to as clinics A to Q) is provided in [Table 1](#t0005){ref-type="table"}. Two clinics (L and P) did not return a questionnaire of general data about their centre (see [Section 2](#s0025){ref-type="sec"}) and in two other cases (clinics H and K) the returned questionnaire was incomplete. Participating clinics were scattered within the Madrid region (14 were located in the capital city, two in other municipalities within the metropolitan area and one in a rural location) and varied widely in their year of opening (from 1981 to 2014), number of cases attended per week (x±S.D.=37.6±18.7 and 16.5±11 for dogs and cats, respectively), number of fecal cultures requested per week (1.6±2.4 and 0.9±1.8), and other parameters ([Table 1](#t0005){ref-type="table"}). These clinics also differed in the antibiotics used for the treatment of diarrhea, but 12 of them (80% for which pharmacological data were available) reported the use of metronidazole for the treatment of these conditions. Only three clinics (20%; F, J and O) acknowledged frequent request of microbiological culturing for anaerobes, and five clinics (33.3%; D, F, H, N and O) reported occasional suspicion of *C. difficile* and/or *C. perfringens* involvement in severe cases of diarrhea.Table 1Overview of the characteristics of the veterinary clinics that participated in the study.[a](#tbl1fna){ref-type="table-fn"}Table 1**ClinicOpening yearNo. cases per week**[b](#tbl1fnb){ref-type="table-fn"}**No. diarrea cases per week**[b](#tbl1fnb){ref-type="table-fn"}**No. fecal samples per week**[b](#tbl1fnb){ref-type="table-fn"}**No. fecal cultures per week**[b](#tbl1fnb){ref-type="table-fn"}A201461 (55 D, 6 C)2.5 (2 D, 0.5 C)1 (1 D)0.5 (0.5 D)B199482 (50 D, 32 C)2.5 (2 D, 0.5 C)3.5 (3 D, 0.5 C)0C200911 (10 D, 1 C)5.5 (5 D, 0.5 C)1 (1 D)0D201440 (22 D, 18 C)8 (7 D, 1 C)7 (5 D, 2 C)0E199340 (20 D, 20 C)2 (2 D)4 (2 D, 2 C)4 (2 D, 2 C)F1981100 (70 D, 30 C)14 (10 D, 4 C)2.3 (2 D, 0.3 C)0.31 (0.3 D, 0.01 C)G198427.5 (16 D, 11.5 C)11.5 (8 D, 3.5 C)1.5 (1 D, 0.5 C)1.5 (1 D, 0.5 C)H200255 (35 D, 20 C)5 (4 D, 1 C)NANAI199270 (60 D, 10 C)8 (7 D, 1 C)1.5 (1 D, 0.5 C)0J200490 (48 D, 42 C)12 (8 D, 4 C)16 (10 D, 6 C)14 (8 D, 6 C)K1985NANA10 (6 D, 4 C)10 (6 D, 4 C)LNANANANANAM200147.5 (35 D, 12.5 C)4.5 (4 D, 0.5 C)4.5 (4 D, 0.5 C)3 (2.5 D, 0.5 C)N199935 (25 D, 10 C)4 (3 D, 1 C)4 (3 D, 1 C)1 (1 D)O201026 (20 D, 6 C)3 (2.5 D, 0.5 C)0.5 (0.5 D)0.5 (0.5 D)PNANANANANAQ200572 (60 D, 12 C)20 (20 D)2 (2 D)0Total[c](#tbl1fnc){ref-type="table-fn"}54.1±25.3 (37.6±18.7 D, 16.5±11 C)7.3±5.1 (6±4.6 D, 1.3±1.4 C)4.2±4.1 (3±2.5 D, 1.2±1.7 C)2.5±4.1 (1.6±2.4 D, 0.9±1.8 C)[^1][^2][^3]

1.2. Demographic and clinical features of recruited animals {#s0015}
-----------------------------------------------------------

The demographic characteristics of recruited animals are summarized in [Table 2](#t0010){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}. A total of 142 animals, including 105 dogs and 37 cats (73.9% and 26.1% of total, respectively; [Fig. 1](#f0005){ref-type="fig"}A) of diverse breeds ([Fig. 2](#f0010){ref-type="fig"}), were recruited for the study. The male/female ratio of animals varied widely among clinics, with the overall values for dogs and cats being similar (56.2%, 43.8% and 56.8%, 43.2%, respectively; [Fig. 1](#f0005){ref-type="fig"}C). The age distribution of sampled animals also showed ample variation among clinics, but the overall values were similar for the dog and cat subpopulations: 20%, 45.7%, 32.4% of dogs and 10.8%, 54.1%, 32.4% of cats had \<1 year, 1--6 years and ≥7 years, respectively ([Table 2](#t0010){ref-type="table"}).Fig. 1Characteristics of the animal populations recruited for this study. A) Bar plot showing the distribution of recruited animals per species: dog, green bars; cats, orange bars. For each participating clinic (A to Q), the overall number of animals is indicated between parentheses. B) Bar plot of the overall age distribution of dogs (*n*=105; green bars) and cats (*n*=37; orange bars) recruited for the study. C) Pie charts of the overall sex distribution of dogs (n=105) and cats (n=37) included in the study. Blue and pink sectors represent male (M) and female (F) subpopulations, respectively. D) Bar plot of the antimicrobial treatments administered to recruited dogs and cats (green and orange bars, respectively) ≤30 days before sampling. E) Bar plot of recent pharmacological treatments administered to recruited dogs and cats (green and orange bars, respectively) ≤30 days before sampling. Abbreviations: ACE, angiotensin-converting-enzyme; NSAIDs, nonsteroidal anti-inflammatory drugs; PPIs, proton pump inhibitors. In panels D and E, pharmacological treatment data were not available for a total of 48 animals (32 dogs and 16 cats).Fig. 1Fig. 2Bar plots showing the breed distribution of recruited dogs (*n*=105, left panel) and cats (*n*=37, right panel). \*Other dog breeds (*n*): Boxer (3), Setter (3), Shih Tzu (3), American Staffordshire Terrier (2), Belgian Shepherd (2), Border Collie (2), Chinese Shar-Pei (2), Cocker Spaniel (2), Golden Retriever (2), Labrador Retriever (2), Pug (2), Shiba Inu (2), Andalusian Hound (1), Chihuahua (1), Dalmatian (1), Galician Palleiro (1), Hound (1), Mastiff (1), Miniature Pinscher (1), Pit bull (1), Poodle (1), Water dog (1).Fig. 2Table 2Overview of the animals that were recruited for this study[a](#tbl2fna){ref-type="table-fn"}.Table 2**Clinic*****N***[b](#tbl2fnb){ref-type="table-fn"}**DogsCats*****n*****Sex ratio**[c](#tbl2fnc){ref-type="table-fn"}**Age distributionDays since last episode of diarrhea*****n*****Sex ratio**[c](#tbl2fnc){ref-type="table-fn"}**Age distributionDays since last episode of diarrhea\<1 yr1--6 yr≥7 yr0≤30\>30\<1 yr1--6 yr≥7 yr0≤30\>30**A662:133.3%66.7%0%0%66.7%33.3%0--------------B15121:525%25%50%25%0%75%32:10%33.3%66.7%0%0%100%C843:150%50%0%0%25%75%41:10%25%75%50%0%50%D321:10%100%0%0%0%100%10:10%0%100%0%0%100%E432:10%66.7%33.3%0%66.7%33.3%10:10%0%100%100%0%0%F1252:30%20%80%0%40%60%74:314.3%85.7%0%0%0%100%G171511:420%40%40%13.3%26.7%60%20:10%100%0%0%0%100%H554:1100%0%0%20%20%60%0--------------I654:120%60%20%40%20%40%11:00%0%100%0%100%0%J\*832:10%66.7%0%33.3%66.7%0%53:220%60%0%40%60%0%K221:00%50%50%0%0%100%0--------------L\*220:10%0%50%50%0%50%0--------------M27224:74.5%59.1%36.4%0%13.6%86.4%53:220%60%20%0%0%100%N\*987:112.5%37.5%50%12.5%0%37.5%11:00%0%100%0%0%100%O1141:125%75%0%0%25%75%75:214.3%57.1%28.6%0%0%100%P110:1100%0%0%100%0%0%0--------------Q665:116.7%50%33.3%33.3%33.3%33.3%0--------------Total\*14210559:4620%45.7%32.4%13.3%21.9%61%3721:1610.8%54.1%32.4%13.5%10.8%75.7%[^4][^5][^6]

The overall proportion of dogs and cats with diarrhea on the sampling date were very similar (13.3% and 13.5%, respectively), and in both cases most animals had not suffered any episode of diarrhea within the preceding 30 days (61% and 75.7%, respectively) ([Table 2](#t0010){ref-type="table"}). Only 24.7% (18/73) of dogs and 14.3% (3/21) of cats for which medication data was available were under antibiotic treatment on the sampling date or within the previous 30 days, with metronidazole and amoxicillin ranking first and second, respectively ([Fig. 1](#f0005){ref-type="fig"}D). Other pharmacological treatments of sampled animals are shown in [Fig. 1](#f0005){ref-type="fig"}E.

The demographic data and clinical features of animals yielding positive fecal cultures for *C. perfringens* and/or *C. difficile* are detailed in [Table 3](#t0015){ref-type="table"} (see also Álvarez-Pérez et al. [@bib1]).Table 3Signalment and clinical data of animals yielding positive fecal cultures for *Clostridium perfringens* and/or *C. difficile*, and characteristics of recovered isolates.Table 3**ClinicAnimal**[a](#tbl3fna){ref-type="table-fn"}**Species, breed**[b](#tbl3fnb){ref-type="table-fn"}**Age (yr.)**[b](#tbl3fnb){ref-type="table-fn"}**SexDiagnosisOther medical conditions of relevanceDiarrhoea**[c](#tbl3fnc){ref-type="table-fn"}**Antibiotic treatment(s)**[d](#tbl3fnd){ref-type="table-fn"}**Genotype (antimicrobial resistances) of*****C. perfringens*****isolates**[e](#tbl3fne){ref-type="table-fn"}**Genotype (antimicrobial resistances) of*****C. difficile*****isolates**[f](#tbl3fnf){ref-type="table-fn"}AA/02Dog, Mixed-breed5FRoutine analysisNoneNoNonep063, p064, p065--BB/02Dog, Whippet13FRoutine analysisLymphomaNoNonep067--B/06Dog, Whippet7FRoutine analysisNoneNoNonep027, p028 \[2 isolates\]--B/07Dog, Schnauzer9FRoutine analysisNoneNoNonep011, p012, p023--B/08Dog, Schnauzer9FRoutine analysisNoneNoNonep002, p047, p051RT154/d05 (PEN), RT154/d06 (PEN), RT154/d07 (PEN)B/11Dog, Mixed Setter\<1FRecent history of *Isospora* infectionNoneYesMetronidazolep035, p036 \[2 isolates\]--B/12Dog, Mixed Miniature Pinscher6FRoutine analysisNoneNoNonep037--B/13Cat, European shorthair9FRoutine analysisNoneNoNonep003 (MTZ), p006, p031--B/14Cat, European shorthair1MRoutine analysisNoneNoNonep069, p072--DD/02Dog, Hound1FRoutine analysisNoneNoNonep087 (MTZ), p088 (LZD), p095--EE/03Dog, Yorkshire Terrier11MGastroenteritis with vomitingHeart failureYes (5 d)Amoxicillin-clavulanic acidNART?/d13 (CLI/ERY/PEN) \[2 isolates\], RT?/d14 (CLI/ERY/PEN)FF/09Cat, Persian6MRoutine analysisNoneNoNonep004, p005--GG/01Dog, Labrador12MRoutine analysisNoneYes (7 d)Doxycyclinep106--Follow-up analysisNoneNoNonep041, p092, p097--G/05Dog, Boxer\<1MRoutine analysisFood allergyNoNonep030 (MTZ), p050, p096--G/06Cat, Persian2FRoutine analysisNoneNoNonep026--HH/03Dog, Mastiff\<1FRoutine analysisNoneNoNonep078 (PEN), p102 (IPM, PEN), p103--H/05Dog, Pit bull\<1MRoutine analysisNoneNoNonep008, p034, p079 (IPM, LZD, PEN)--II/02Cat, European shorthair14MDigestive diseaseNoneYes (3 d)Nonep054, p055--I/04Dog, Mixed-breed1HDigestive diseaseNoneYes (0 d)Nonep082, p099--Follow-up analysisNoneNoNonep052 (LZD)--JJ/01Dog, Schnauzer?FRoutine analysisFood allergyYes (10 d)Nonep053, p058 (ERY, LVX)--J/03Dog, Golden Retriever4MAcute enteritisNoneYes (0 d)Nonep013, p017, p018--J/07Dog,?1MRoutine analysisNoneYes (8 d)Nonep101--KK/02Dog, Poodle10MRoutine analysisHeart murmurNoNonep089--MM/04Dog, Giant Schnauzer11FRoutine analysisNoneYes (30 d)Nonep090\[2 isolates\], p091--Follow-up analysisNoneYes (5 d)Nonep043 (TET), p076 (TET), p077--M/06Dog, Brittany6FRoutine analysisObesityNoNonep060, p061, p066--Follow-up analysisObesityNoNonep068, p070 (TET), p104--M/07Dog, Brittany3FEntetitisRecent *Toxocara canis* infection, obesityYes (25 d)Nonep081--Follow-up analysisObesityNoNonep033, p042 (TET), p056--M/08Dog, Mixed Hound3FRoutine analysisNoneNoNonep040, p062, p080--M/13Cat, European shorthair4FRoutine analysisNoneNoNonep025, p029, p071--M/14Dog, Mixed-breed8FRoutine analysisRecent removal of mammary tumorNoAmoxicillinp016, p020, p021RT106/d01 (PEN), RT106/d03 (PEN), RT106/d15 (PEN)Follow-up analysisNoneNoNonep014\[2 isolates\], p015--M/23Dog, Yorkshire Terrier12FRoutine analysisFrequent pseudo-pregnancies, benign mammary tumorsNoNonep032--M/25Dog, German Shepherd5FRoutine analysisObesityNoNonep001 (TET), p057--Follow-up analysisObesityNoNonep083 (TET), p084 (LZD, TET), p085 (LZD. TET)--M/26Dog, Mixed-breed2MRoutine analysisSeizure disorderNoNonep038, p039--Follow-up analysisSeizure disorderNoNonep086 (MTZ), p093, p100--NN/01Dog, Mixed Shih Tzu1MRoutine analysisNoneNoNonep044, p045, p046--N/12&14[g](#tbl3fng){ref-type="table-fn"}Dog, Shih Tzu12MRoutine analysisNoneYes (0 d)Nonep019, p024--N/19&20[g](#tbl3fng){ref-type="table-fn"}Dog, French Bulldog7MRoutine analysisNoneNoNone--RT009-like/d04, RT009-like/d08 (PEN), RT009-like/d09 (PEN), RT009-like/d10 (PEN), RT009-like/d11 (PEN), RT009-like/d12OO/04Cat, European shorthair4MRoutine analysisNoneNoNonep094--O/11Dog, Border Collie2MRoutine analysisNoneYes (7 d)Nonep007, p009, p010--QQ/03Dog, Maltese7MRoutine analysisFrequent gastrointestinal problems, heart diseaseNoNonep073 (MTZ), p074, p075 (LZD)RT106/d01 (PEN) \[2 isolates\], RT106/d02 (PEN)Q/04Dog, Mixed Labrador2MAllergic colitisFrequent gastrointestinal problemsYes (0 d)Sulfadiazine/trimethoprimp059--Follow-up analysisNoneNoNonep022, p098--Q/05Dog, Dachshund14MRoutine analysisNoneNoNonep048, p049--[^7][^8][^9][^10][^11][^12][^13]

1.3. Genetic and phenotypic characteristic of *C. perfringens* and *C. difficile* isolates {#s0020}
------------------------------------------------------------------------------------------

[Table 3](#t0015){ref-type="table"} includes an overview of the genetic and phenotypic characteristics of the bacterial isolates obtained from recruited animals. Additionally, the toxinotypes, PCR ribotypes (only for *C. difficile* isolates), amplified fragment length polymorphism (AFLP) genotypes and antimicrobial susceptibility profiles of *C. perfringens* and *C. difficile* isolates are detailed in [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, respectively.Table 4Characteristics of the *Clostridium perfringens* isolates obtained in the study.Table 4**Isolate**[a](#tbl4fna){ref-type="table-fn"}**Toxinotype**[b](#tbl4fnb){ref-type="table-fn"}**AFLP genotype**[c](#tbl4fnc){ref-type="table-fn"}**Antibiotic susceptibility (MIC, µg/ml)**[d](#tbl4fnd){ref-type="table-fn"}**AMCCLIERYIPMLVXLZDMTZPENRIFTECTETTGCVAN**A/02P1A (*cpe*, *cpb2*\*)p0630.1250.2520.0640.54160.50.0080.064811A/02P2A (*cpb2*\*)p0640.0320.0320.0640.0640.250.12580.1250.0040.03240.1250.5A/02P3A (*cpe*)p0650.0320.0320.0320.0640.250.12580.0640.0020.0320.1250.0640.5B/02P1Ap0670.0320.06420.0640.254160.0640.008\<0.0160.1250.0640.5B/06P1A (*cpb2*\*)p0270.0640.06420.0640.254160.0320.004\<0.01640.250.5B/06P2A (*cpb2*\*)p0280.0320.12520.50.254160.1250.0040.03240.50.5B/06P3A (*cpb2*\*)p028\<0.0160.520.50.254160.0640.0080.03240.50.5B/07P1A (*cpe*)p0110.0320.12510.0320.254160.0320.004\<0.01620.1250.25B/07P2A (*cpe*)p0120.0320.12520.0640.254160.0640.0080.03240.1250.25B/07P3A (*cpe*)p023\<0.0160.12520.0640.252160.1250.0080.03240.1250.25B/08P1A (*cpb2*\*)p0470.0320.06420.1250.254160.0640.004\<0.01640.1250.5B/08P2A (*cpb2*\*)p0020.0320.2520.0640.252160.0640.0080.03220.50.5B/08P3A (*cpb2*\*)p0510.0160.12520.1250.254160.0640.0080.03240.250.5B/11P1A (*cpb2*\*)p0350.1250.01610.0640.251160.1250.004\<0.01640.1250.5B/11P2A (*cpb2*\*)p0360.0160.2520.0640.25280.1250.0040.01640.50.5B/11P3A (*cpb2*\*)p0360.0320.2520.0080.52160.1250.0040.03240.50.5B/12P1Ap0370.0320.0160.1250.0640.25180.0320.004\<0.01610.1250.5B/13P1A (*cpb2*\*)p0030.0640.06420.0320.5432 (R)0.0640.0080.03220.0640.5B/13P2Ap0060.0320.06420.250.54160.1250.0040.06480.1250.5B/13P3Ap0310.0640.2520.0640.254160.1250.008\<0.01680.1250.5B/14P1Ap0690.0640.12520.0640.52160.250.0080.03240.250.5B/14P2Ap0720.032220.0320.25\<0.01680.0640.004\<0.01640.250.5D/02P1E (*cpe*)p0870.064\<0.01610.50.25232 (R)0.0640.0020.03240.0640.5D/02P2E (*cpe*)p0880.0640.06440.1250.258 (R)80.1250.0040.03240.251D/02P3E (*cpe*)p0950.0320.03210.0640.51160.1250.0040.03220.250.5F/09P2Ap0040.1250.0640.50.250.250.580.250.0040.0320.1250.0640.5F/09P3Ap0050.0640.064210.25480.250.0080.06440.0641G/01P1Ap1050.0640.0640.0640.0640.51160.0640.004\<0.01610.1250.5G2/01P1†A (*cpb2*\*)p0920.0640.06440.1250.25480.1250.0080.06440.250.5G2/01P2†A (*cpb2*\*)p0970.064\<0.0160.0640.1250.254160.1250.0080.01640.0640.5G2/01P3†A (*cpb2*\*)p0410.0320.12520.0640.25480.1250.0040.01680.250.5G/05P1A (*cpb2*\*)p0300.1250.06420.0640.25432 (R)0.1250.0080.03280.1250.5G/05P2A (*cpb2*\*)p0500.0640.2510.0640.25280.50.004\<0.01640.250.5G/05P3Ap096\<0.0160.12510.0320.5440.1250.004\<0.01640.1250.5G/06P1Ap0260.1250.12520.0640.54160.1250.0080.03280.251H/03P1Ap10280.1252≥32 (R)0.254168 (R)0.0040.03280.1250.5H/03P2Ap07840.032210.254168 (R)0.0040.03240.1250.5H/03P3Ap1030.0320.06410.1252280.0640.0040.06480.50.5H/05P1Ap07980.1252≥32 (R)0.258 (R)168 (R)0.0040.03280.50.5H/05P2Ap0080.0320.12510.0640.25140.0640.0020.01640.1250.5H/05P3Ap034\<0.0160.06420.1250.254160.0320.0080.03240.1250.5I/02P1Ap0540.0640.06420.1250.252160.1250.0040.01640.1250.5I/02P2Ap0550.032\<0.01640.0640.50.25160.064\<0.002\<0.01640.0640.5I/04P1A (*cpe*)P0990.1250.0320.250.1250.251160.1250.0040.0320.1250.0320.5I/04P2Ap0820.0320.2520.0320.250.5160.125\<0.002\<0.01640.1250.5I2/04P1†A (*cpe*)p0520.0320.12520.0640.258 (R)160.1250.0080.03240.250.5J/01P1A (*cpb2*\*)p0530.0640.12520.0640.54160.1250.0080.03280.51J/01P2A (*cpb2*\*)p0580.0640.2532 (R)0.125≥32 (R)2160.1250.0080.03240.1250.5J/03P1Ap0180.0640.03220.0640.54160.0640.004\<0.0160.1250.0640.5J/03P2A (*cpb2*\*)p0130.1250.0320.1250.0640.254160.064\<0.002210.0322J/03P3A (*cpb2*\*)p0170.0160.0320.1250.0320.252160.0640.004\<0.01620.0320.5J/07P1A (*cpb2*)p1010.016\<0.0160.1250.0640.251160.0320.0080.0320.1250.0320.5K/02P1Ap0890.0320.12520.50.254160.1250.0040.03240.1250.5M/04P1A (*cpe*)p0900.0640.12520.0640.254160.1250.0080.06480.50.5M/04P2A (*cpe*)p0900.0320.125210.54160.0640.0040.06440.50.5M/04P3A (*cpe*)p0910.032\<0.016\<0.0160.50.254160.0640.0160.06440.1250.5M2/04P1†A (*cpb2*\*)p0430.0320.03220.250.254160.0320.0040.01616 (R)10.5M2/04P2†A (*cpb2*\*)p0760.0320.06420.50.25480.0640.0080.01616 (R)0.50.5M2/04P3†A (*cpb2*\*)p0770.0320.0320.0640.0640.5280.0640.0040.01640.250.5M/06P1A (*cpb2*\*)p0660.1250.06420.0640.254160.50.0080.064821M/06P2A (*cpb2*\*)p0600.0320.06410.0640.252160.1250.0040.03240.250.5M/06P3A (*cpe*, *cpb2*\*)p0610.0320.0320.50.1250.254160.1250.0040.03240.1250.5M2/06P1†Ap0680.0640.06420.50.54160.250.0080.03280.1250.5M2/06P2†Ap0700.0160.12520.0320.254160.1250.0040.03216 (R)0.50.5M2/06P3†Ap1040.0640.0320.250.1250.25480.1250.0080.01640.50.5M/07P1Ap0810.250.03220.1250.254810.0080.03240.50.5M2/07P1†A (*cpb2*\*)p042\<0.0160.03220.0640.254160.1250.0080.01616 (R)10.5M2/07P2†Ap0560.0320.06440.1250.25480.1250.0040.03240.250.5M2/07P3†Ap0330.0320.06410.1250.5480.250.0080.03280.250.5M/08P1A (*cpb2*\*)p0620.0640.520.0640.254160.25\<0.0020.032820.5M/08P2Ap0400.0320.0640.250.0640.254160.1250.0080.01610.0640.5M/08P3Ap0800.032\<0.0160.0320.0640.5180.064\<0.0020.03240.1250.5M/13P1A (*cpb2*\*)p0290.1250.2520.0640.254160.0640.0040.032841M/13P2A (*cpb2*\*)p0250.0320.0320.0320.0320.250.12580.064\<0.0020.03240.0320.5M/13P3A (*cpe*)p0710.032120.1250.5280.0640.0020.03240.1250.5M/14P1A (*cpe*)p0160.0160.06420.0640.25480.0640.0040.0160.1250.0640.5M/14P2A (*cpe*)p0200.1250.520.0640.25240.1250.004\<0.01620.0320.5M/14P3A (*cpe*)p0210.0320.12520.0320.25280.0640.0080.01640.1250.5M2/14P1†A (*cpb2*\*)p014\<0.0160.03220.1250.25180.064\<0.0020.01640.1250.5M2/14P2†A (*cpb2*\*)p0150.0640.0320.0320.0640.252160.0640.0040.01640.50.5M2/14P3†A (*cpb2*\*)p0140.0640.03220.1250.252160.0640.0040.01640.50.5M/23P1A (*cpb2*)p0320.0640.2520.0160.252160.250.0080.03240.1251M/25P1Ap0010.125240.0640.54160.250.0080.12516 (R)21M/25P2Ap0570.0320.01620.0640.25280.0320.0020.06480.1250.5M2/25P1†Ap0830.0320.12520.0640.5480.1250.0040.06416 (R)10.5M2/25P2†Ap0840.0320.12520.1250.258 (R)80.1250.0080.03216 (R)20.5M2/25P3†Ap0850.0320.12520.1250.258 (R)80.1250.0040.03216 (R)10.5M/26P1Ap0390.1250.12540.0640.254160.250.0040.03280.251M/26P2Ap0380.032\<0.01610.0640.25280.0640.0020.01680.0640.5M2/26P1†Ap1000.0320.032210.254160.1250.0040.03240.250.5M2/26P2†Ap0860.0160.06420.1250.5432 (R)0.1250.0080.03220.1250.5M2/26P3†A (*cpb2*\*)p0930.0160.06420.50.5480.0640.0040.03240.250.5N/01P1A (*cpb2*\*)p0440.1250.12520.0640.254160.0640.004\<0.01680.251N/01P2A (*cpb2*\*)p0450.0320.06420.0640.54160.250.0040.06480.50.5N/01P3A (*cpb2*\*)p0460.0320.12540.0640.5180.1250.004\<0.01680.250.5N/12P1A (*cpe*)p0240.0640.06420.1250.254160.0640.0080.03240.50.5N/14P1Ap0190.0320.0320.250.1250.25280.0320.004\<0.01640.1250.5O/04P1Ap0940.1250.06420.250.2541610.0080.03240.1250.5O/11P1A (*cpb2*\*)p0070.064\<0.0160.0640.0640.25480.125\<0.0020.01640.1250.5O/11P2Ap0090.0320.06410.0320.25180.0320.0040.03280.1250.5O/11P3Ap0100.0320.06420.0640.25280.0640.0040.03280.1250.5Q/03P1Ap0730.1250.01620.0640.25432 (R)0.0640.004\<0.01640.1250.5Q/03P2Ap0750.0640.03220.1250.258 (R)80.250.0080.03240.1250.5Q/03P3Ap0740.0320.12520.1250.254160.1250.0080.03240.250.5Q/04P2Ap0590.0320.12520.1250.254160.1250.0040.01640.1250.5Q2/04P1†A **(***cpb2*\***)**p022\<0.0160.12520.0640.254160.1250.0040.01640.250.5Q2/04P3†Ap0980.0320.01640.0640.254160.1250.0040.03220.1250.5Q/05P1A (*cpb2*\*)p0480.016\<0.0160.250.0640.51160.016\<0.002\<0.01610.1250.5Q/05P2A (*cpb2*\*)p049\<0.0160.12520.0640.52160.250.0040.01640.1250.5[^14][^15][^16][^17]Table 5Characteristics of the *Clostridium difficile* isolates obtained in the study.Table 5**Isolate**[a](#tbl5fna){ref-type="table-fn"}**PCR ribotype**[b](#tbl5fnb){ref-type="table-fn"}**AFLP genotype**[c](#tbl5fnc){ref-type="table-fn"}**Antibiotic susceptibility (MIC, µg/ml)**[d](#tbl5fnd){ref-type="table-fn"}**AMCCLIERYIPMLVXLZDMTZPENRIFTECTETTGCVAN**B/08D1RT154d0610.1250.25≥32 (R)≥32 (R)0.250.064≥32 (R)\<0.0020.0640.0320.0160.25B/08D2RT154d070.250.0640.25≥32 (R)≥32 (R)0.250.0322 (R)\<0.0020.0320.0320.0320.125B/08D3RT154d050.1250.0320.064≥32 (R)≥32 (R)0.1250.03232 (R)\<0.0020.064\<0.016\<0.0160.125E/03D1RT?d130.5≥256 (R)≥256 (R)≥32 (R)≥32 (R)10.032≥32 (R)\<0.0020.0640.5\<0.0160.125E/03D2RT?d130.25≥256 (R)≥256 (R)≥32 (R)≥32 (R)0.50.064≥32 (R)0.0040.03210.0320.125E/03D3RT?d140.5≥256 (R)≥256 (R)≥32 (R)≥32 (R)10.125≥32 (R)\<0.0020.0320.50.0320.125M/14D1RT106d150.50.0640.125≥32 (R)≥32 (R)0.250.064≥32 (R)\<0.0020.032\<0.016\<0.0160.125M/14D2RT106d010.250.251≥32 (R)≥32 (R)0.1250.0644 (R)0.0040.032\<0.016\<0.0160.25M/14D3RT106d030.50.1250.25≥32 (R)≥32 (R)0.50.1252 (R)\<0.0020.0320.032\<0.0160.125N/19D1RT009-liked080.50.0640.25≥32 (R)≥32 (R)0.50.0324 (R)\<0.0020.0640.032\<0.0160.25N/19D2RT009-liked040.064\<0.0160.016≥32 (R)≥32 (R)0.064\<0.0161\<0.0020.032\<0.016\<0.0160.125N/19D3RT009-liked090.25\<0.0160.064≥32 (R)≥32 (R)0.125\<0.0164 (R)\<0.0020.0320.032\<0.0160.125N/20D1RT009-liked100.250.0640.125≥32 (R)≥32 (R)0.250.032≥32 (R)\<0.0020.0320.032\<0.0160.25N/20D2RT009-liked1110.0160.032≥32 (R)≥32 (R)0.250.064≥32 (R)\<0.0020.032\<0.0160.0320.125N/20D3RT009-liked1210.1250.25≥32 (R)≥32 (R)0.1250.0641\<0.0020.064\<0.016\<0.0160.125Q/03D1RT106d010.250.0640.064≥32 (R)≥32 (R)0.1250.032≥32 (R)\<0.0020.032\<0.016\<0.0160.125Q/03D2RT106d020.250.0640.25≥32 (R)≥32 (R)0.1250.0322 (R)\<0.0020.0640.0320.0320.25Q/03D3RT106d010.250.1250.125≥32 (R)≥32 (R)0.250.0322 (R)\<0.0020.0640.064\<0.0160.25[^18][^19][^20][^21]

2. Experimental design, materials and methods {#s0025}
=============================================

Our survey was performed during one week (from November 24 to December 1, 2015) in a total of 17 primary care veterinary clinics from the Madrid region (Spain). The staff of participating clinics received training for data and sample collection, and email and telephonic support was available throughout the duration of the study. Veterinarians of participating centers were asked to select two swab samples of all feces shed by dogs and cats at their clinic, regardless of the age, origin and clinical condition of the animals, and to send those samples to a central reference laboratory at the Faculty of Veterinary Medicine of Complutense University of Madrid. Additionally, the staff of each participating clinic had to complete a questionnaire of general data about the centre and a second questionnaire for each pair of fecal swabs obtained requesting data on the sample (collection date, consistency of feces and presence of blood) and the animal of origin (species, breed, sex, age, clinical status and episodes of diarrhea and medication(s) within the previous 30 days). An informed consent and agreement to participate in the study was obtained from the owners of each animal before enrolment. Animals were always handled by experienced veterinary practitioners in strict accordance with good animal practice and the Spanish legislation.

The owners of animals yielding a positive culture for *C. difficile* and/or *C. perfringens* were invited to participate in a follow-up survey performed four months after the first study (in March 2016). In this case, fecal swab samples and clinical information of animals was obtained as explained above.

The microbiology procedures used for *C. perfringens* and *C. difficile* isolation from fecal samples, and the methods used for toxin profiling, PCR ribotyping, AFLP subtyping and *in vitro* antimicrobial susceptibility testing of recovered isolates are detailed in our previous publication [@bib1].
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[^1]: See also [Fig. 1](#f0005){ref-type="fig"}.

[^2]: D, dogs; C, cats. All figures refer to the last 12-month period.

[^3]: x±S.D.

[^4]: See also [Fig. 1](#f0005){ref-type="fig"}. Asterisks indicate that there were some recruited animals with missing data and thus the sum of percentages can be \<100%.

[^5]: Total number of animals that were recruited (i.e. dogs and cats).

[^6]: Number of males: number of females.

[^7]: Recruited animals were designated by a capital letter (corresponding to the clinic of origin) followed by a virgule and consecutive numbers.

[^8]: ?: Missing data.

[^9]: No: no diarrhea episodes were reported within the previous 30 days. For positive responses, the number of days since the last episode of diarrhea is indicated between parentheses.

[^10]: Antibiotic treatment(s) administered within the previous 30 days. For an overview of other pharmacological treatments see [Fig. 1](#f0005){ref-type="fig"}E.

[^11]: AFLP genotypes were arbitrarily designated by a lower case 'p' followed by a number (see [Table 4](#t0020){ref-type="table"}). *In vitro* resistance to benzylpenicillin (PEN), erythromycin (ERY), imipenem (IPM), levofloxacin (LVX), linezolid (LZD), metronidazole (MTZ) and/or tetracycline (TET) is indicated between parentheses. The number of isolates belonging to each strain type (when different to one) is shown between square brackets. Dashes mean that *C. perfringens* was not isolated from the corresponding animal. NA: not analyzed (a single fecal swab was available for some animals, and this was used for *C. difficile* testing).

[^12]: In this case, ribotype (RT) and AFLP fingerprinting information is included. AFLP genotypes were arbitrarily designated by a lower case 'd' followed by a number (see [Table 5](#t0025){ref-type="table"}). *In vitro* resistance to benzylpenicillin (PEN), clindamycin (CLI) and/or erythromycin (ERY) is indicated between parentheses. Additionally, all *C. difficile* isolates displayed resistance to levofloxacin and imipenem. The number of isolates belonging to each strain type (when different to one) is shown between square brackets. RT?: unknown ribotype. Dashes mean that *C. difficile* was not isolated from the corresponding animal.

[^13]: These animals were sampled twice during the study period.

[^14]: Isolates whose names only differ in the last number were retrieved from the same animal (e.g. H/05P1, H/05P2 and H/05P3; see [Table 3](#t0015){ref-type="table"}). Daggers (and the number 2 after the clinic\'s code) indicate isolates that were obtained in the follow-up analysis.

[^15]: *cpe*: possession of the gene encoding for enterotoxin. *cpb2*: possession of the gene encoding for β2 toxin, with asterisks indicating atypical forms of the gene (as determined by PCR amplification).

[^16]: According to the UPGMA dendrogram shown in [Fig. 1](#f0005){ref-type="fig"} of Álvarez-Pérez et al. [@bib1].

[^17]: Minimum inhibitory concentration (MIC). AMC, amoxicillin/clavulanic acid; CLI, clindamycin; ERY, erythromycin; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MTZ, metronidazole; PEN, benzylpenicillin; RIF, rifampicin; TEC, teicoplanin; TET, tetracycline; TGC, tigecycline; VAN, vancomycin. R: MIC value above the breakpoint for *in vitro* resistance.

[^18]: Isolates were retrieved from the same animal (B/08D1, B/08D2 and B/08D3; see [Table 3](#t0015){ref-type="table"}).

[^19]: Toxin profiles: RT009-like, A-B-CDT- (but with a positive PCR result for *tcdB*); RT106, A+B+CDT-; RT154, A+B+CDT-; RT? (unknown ribotype), A-B-CDT-.

[^20]: According to the UPGMA dendrogram shown in [Fig. 2](#f0010){ref-type="fig"} of Álvarez-Pérez et al. [@bib1].

[^21]: Minimum inhibitory concentration (MIC). AMC, amoxicillin/clavulanic acid; CLI, clindamycin; ERY, erythromycin; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MTZ, metronidazole; PEN, benzylpenicillin; RIF, rifampicin; TEC, teicoplanin; TET, tetracycline; TGC, tigecycline; VAN, vancomycin. R: MIC value above the breakpoint for *in vitro* resistance.
